Treatment with Oral Ondansetron for Ultramarathon-Associated Nausea: The TOO FUN Study.

Andrew V Pasternak, David Fiore, Arthur Islas, Sarah Toti, Martin D Hoffman

Open access · goldAbstract read

In one paragraph

Article in Sports (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 47% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew V PasternakSilver Sage Center for Family Medicine, Reno, NV 89521, USA.

David FioreDepartment of Family and Community Medicine, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.

Arthur IslasDepartment of Family and Community Medicine, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.

Sarah TotiReno School of Medicine, University of Nevada, Reno, NV 89557, USA.ORCID 0000-0002-9953-5229

Martin D HoffmanPhysical Medicine and Rehabilitation Service, Department of Veterans Affairs, Northern California Health Care System, Sacramento, CA 95655, USA.ORCID 0000-0001-8819-5989

University of Nevada, Reno · USVA Northern California Health Care System · US

Funding

CSRD VA 1

6 · The paper itself

Abstract

Nausea and vomiting are common for runners during ultramarathons and often contribute to non-finishes. We aimed to determine the efficacy of ondansetron, a commonly used antiemetic, to treat nausea and vomiting in runners during an ultramarathon. Runners who had a previous history of frequent nausea or vomiting during races and entered in 160, 80, and 55 km ultramarathons in 2018 and 2019 were randomized in a double-blind fashion to 4 mg ondansetron or placebo capsules to use if they developed nausea or vomiting during the race with the ability to take three additional doses. Study participants completed a post-race online survey to assess medication use and efficacy. Of 62 study participants, 31 took either ondansetron (20) or placebo (11). In this small study, there were no group differences in those reporting any improvement in nausea and vomiting (

Indexed as

antiemeticendurance exerciserandomized controlled trialrunningserotonin 5-HT3 receptor antagonist

Identifiers

PMID33802399

DOI10.3390/sports9030035

PMCPMC8001581

OpenAlexW3134361983

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.